PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is concentrating its drug-development investments on targeted cancer therapies while pursuing partnerships to limit future financing requirements, a strategic shift that follows approximately $90 million in capital raised over three years and a period of stock-price volatility.
The biotechnology company is prioritizing CD228V, an investigational antibody-drug conjugate targeting melanotransferrin, or CD228, as the centerpiece of its precision oncology strategy. Two additional programs, SkinJect and Teverelix, provide development opportunities in rare skin disorders, urology and women’s health.
The strategy reflects Medicus’ transition from a company primarily focused on SkinJect into a broader drug-development business built through acquisitions, clinical investments and regulatory work.
Since beginning operations in October 2023, Medicus has raised approximately $90 million through equity and debt financing. The company moved from the TSX Venture Exchange to Nasdaq in November 2024, expanding its access to U.S. capital markets.
Those investments have supported clinical development, acquisitions and organizational operations, but have yet to establish the commercial potential of the company’s investigational therapies.
Medicus acknowledged that its expansion has coincided with stock-price volatility and a pullback, placing greater emphasis on demonstrating clinical progress and controlling future spending.
The company’s immediate oncology priority is CD228V, which uses Pfizer’s established vedotin linker-payload platform to deliver a cancer-killing agent through an antibody designed to recognize a protein expressed on certain tumor cells.
Initial development will focus on melanoma, particularly patients whose disease has relapsed, resisted treatment or failed to respond to immunotherapy.
Medicus intends to incorporate biomarker analysis into the development program to identify patients who may be more likely to benefit from treatment.
The company also sees potential applications in lung, head and neck, and esophageal cancers that express CD228, although those opportunities remain exploratory.
CD228V has an existing clinical and manufacturing foundation, but its effectiveness and safety advantages have not been established. No approved therapy has validated CD228 as a therapeutic target.
That uncertainty makes clinical evidence central to the program’s development prospects and its potential value to pharmaceutical partners.
Medicus is also advancing SkinJect, a localized treatment candidate for basal cell carcinomas in patients with Gorlin syndrome, a rare inherited disorder associated with recurrent skin cancers.
The company completed its SKNJCT-003 Phase 2 study and selected a 200-microgram dose for further development.
The U.S. Food and Drug Administration subsequently authorized Medicus to initiate SKNJCT-005, a planned registrational study evaluating the treatment in patients with Gorlin syndrome.
The authorization allows the company to proceed with the study but does not establish that SkinJect is effective or that it will receive marketing approval.
The program targets patients who frequently require repeated procedures to manage recurring basal cell carcinomas, providing a defined population for evaluating a localized treatment approach.
Medicus’ third principal asset, Teverelix, entered its portfolio through the August 2025 acquisition of Antev.
The investigational gonadotropin-releasing hormone antagonist is being developed for potential applications in urology and women’s health.
The company has narrowed its development priorities to preventing recurrent acute urinary retention and treating symptomatic endometriosis.
For advanced prostate cancer, Medicus is pursuing a partnership-led strategy focused on patients with elevated cardiovascular risk.
It has submitted an optimized registrational protocol for advanced prostate cancer that incorporates previously FDA-cleared dose-optimization work into a proposed development program.
The protocol remains subject to FDA review.
Medicus also reduced the royalty rate associated with Teverelix following the acquisition, improving the program’s underlying economics. The company did not specify the revised rate in its shareholder update.
Across the portfolio, Medicus intends to direct spending toward selected clinical and regulatory milestones while seeking licensing, co-development and other strategic transactions.
Such arrangements could provide funding that does not require issuing additional equity while transferring portions of future development costs to partners.
The company cautioned that the timing, terms and completion of potential agreements remain uncertain.
The approach places greater weight on external partnerships as Medicus seeks to advance multiple investigational assets without bearing the full cost of development internally.
Its ability to generate value from the portfolio will depend on clinical results, regulatory progress and the commercial terms of any agreements it secures.
For investors, the next phase will test whether Medicus can convert the assets acquired and developed during its first three years into clinical evidence and partnerships sufficient to support continued development while limiting additional capital requirements.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.